Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs ASTX 295 (Primary)
Indications Glioblastoma; Liposarcoma; Malignant-mesothelioma; Sarcoma; Solid tumours; Uveal melanoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Astex Pharmaceuticals; Taiho Oncology

09 Jan 2025 Status changed from active, no longer recruiting to discontinued due to Sponsor decision
03 Apr 2024 According to Astex Pharmaceuticals media release, data from the study will be presented at the American Association For Cancer Research (AACR) 2024 Annual Meeting
08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com